Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations

Management of advanced hepatocellular carcinoma is challenging. With an increasing number of options for the first and second-line treatment, understanding and developing optimal systemic treatment strategies are crucial. In second line, two tyrosine kinase inhibitors (TKI) and one monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Debaillon Vesque, Audrey, Decraecker, Marie, Blanc, Jean-Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293396/
https://www.ncbi.nlm.nih.gov/pubmed/32607316
http://dx.doi.org/10.2147/JHC.S195570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293396/
https://www.ncbi.nlm.nih.gov/pubmed/32607316
http://dx.doi.org/10.2147/JHC.S195570

Ejemplares similares